Simcyp has expanded the capabilities of its population-based drug absorption, distribution, metabolism and excretion (ADME) simulator with the launch of version 9.0.
Version 9.0 was developed in consultation with the Simcyp Consortium of global pharmaceutical companies including Pfizer, Astrazeneca and Johnson and Johnson.
The consortium's priority was the implementation of a model accommodating the effects of influx and efflux transporters, which are increasingly becoming a focus for regulatory agencies including the US Food and Drug Administration.
The transporter feature advances the Simcyp simulator's ability to reflect 'real-life' population variability in the processes of drug ADME through the conduct of studies in virtual human populations.
Drug development researchers using Simcyp Version 9.0 now have the capability of modelling the absorption of drugs that are inhaled or applied to the skin.
In addition, enhancements to trial design elements within the simulator provide greater flexibility to assess the potential outcomes of Phase I, II or III clinical trials early in the drug development process.
Examining complex and potentially dangerous scenarios and assessing the likelihood of such cases in the safety of a computer allows clinical studies to be optimised, prioritised or even abandoned.
